AFP DEPARTMENT COLLECTION
This department includes information about new drugs from the perspective of the five attributes to be considered when weighing the advantages of one drug over another: Safety, Tolerability, Effectiveness, Price, and Simplicity.
Oct 15, 2018 Issue
Recombinant Zoster Vaccine (Shingrix) for the Prevention of Shingles
Recombinant zoster vaccine is a relatively new shingles vaccine that has been shown to have greater effectiveness and protection than the existing live vaccine. Local and systemic adverse effects may occur after administration, but have been shown to resolve within one to three days.
Sep 15, 2018 Issue
Crisaborole (Eucrisa) for Mild to Moderate Atopic Dermatitis
Crisaborole has been shown to be effective in about one-third of patients who use it, but it is much more expensive than other available products. Although crisaborole is a safe option for patients in whom topical corticosteroids are considered risky (e.g., children at least two years of age), it should not be routinely considered until long-term effectiveness and safety data become available.
Aug 15, 2018 Issue
Delafloxacin (Baxdela) for Skin Infections
Delafloxacin is a new fluoroquinolone antibiotic available in intravenous and oral formulations for the treatment of serious skin and skin structure infections in patients requiring initial intravenous therapy. It is effective for infections caused by MRSA or P. aeruginosa, in addition to other common causative pathogens, but has not been shown to be more effective than existing antibiotic regimens.
Jul 15, 2018 Issue
Lifitegrast Ophthalmic Solution 5% (Xiidra) for Dry Eye Disease
Studies have shown that lifitegrast will reduce the symptoms of dry eye disease in some patients, although the benefit is borderline clinically significant. It is much more expensive than over-the-counter ointments, artificial tears, and lubricant eye drops.
Jun 15, 2018 Issue
Oxymetazoline Hydrochloride 1% Cream (Rhofade) for Persistent Facial Erythema Associated with Rosacea
Oxymetazoline cream has been shown to be safe and effective at reducing erythema in a small portion of treated patients, but research showing its effectiveness relative to other options is lacking.
May 15, 2018 Issue
Implantable Buprenorphine (Probuphine) for Maintenance Treatment of Opioid Use Disorder
Implantable buprenorphine is an expensive alternative for patients on a stable dosage of transmucosal buprenorphine. Based on current research and guidance, implantable buprenorphine should not be used as initial treatment for opioid dependence or as a substitute for medication-assisted treatments other than transmucosal buprenorphine.
Apr 15, 2018 Issue
Edoxaban (Savaysa) for the Prevention of Thromboembolic Events
Edoxaban is an alternative to warfarin and other oral anticoagulants for the prevention of stroke in patients with nonvalvular atrial fibrillation and for the treatment of deep venous thrombosis and pulmonary embolism.
Mar 15, 2018 Issue
Lesinurad (Zurampic) for Gout
Lesinurad taken in addition to a xanthine oxidase inhibitor reduces serum uric acid levels. However, it does not reduce the likelihood of experiencing a gout flare-up or completely resolving tophi.
Jan 15, 2018 Issue
Nebivolol/Valsartan (Byvalson) for Hypertension
Nebivolol/valsartan is an option for the treatment of patients with newly diagnosed or poorly controlled hypertension. Although it offers a new beta-blocker option, no research has demonstrated its benefit over existing treatments.
Nov 15, 2017 Issue
Reslizumab (Cinqair) for Eosinophilic Asthma
Reslizumab is an expensive treatment option for decreasing exacerbations in patients with severe asthma and pronounced eosinophilia. Because of the risk of anaphylaxis, it should only be administered in an appropriate facility by a medical professional. Reslizumab is best considered after other treatments have proved ineffective.